A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells.
Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, Zeng J, Nascimento PR, Sequeira VB, Butler TL, Allanson M, Fath T, Hill TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PW.
Stehn JR, et al. Among authors: cripe tp.
Cancer Res. 2013 Aug 15;73(16):5169-82. doi: 10.1158/0008-5472.CAN-12-4501.
Cancer Res. 2013.
PMID: 23946473